Renal Osteodystrophy: A Comprehensive Overview
Renal osteodystrophy (ROD) is the specific skeletal pathology that develops in chronic kidney disease (CKD), characterized by alterations in bone turnover, mineralization, and volume that can only be definitively diagnosed by bone biopsy. 1
Definition and Terminology
ROD should be distinguished from the broader syndrome of CKD-Mineral and Bone Disorder (CKD-MBD). While CKD-MBD encompasses the entire systemic disorder including biochemical abnormalities (calcium, phosphate, PTH, vitamin D), vascular calcification, and bone disease, ROD refers exclusively to the bone pathology itself 1. This distinction is critical for clinical communication and treatment planning.
Pathophysiology
The development of ROD begins early in CKD progression through multiple interconnected mechanisms 2, 3:
Primary Drivers
- Phosphate retention: Occurs as GFR declines, leading to hyperphosphatemia and increased bone resistance to PTH 4
- Calcitriol deficiency: Impaired 1-alpha hydroxylation in damaged kidneys reduces active vitamin D synthesis 2, 3
- Hypocalcemia: Results from decreased calcitriol and stimulates PTH secretion 2
- Secondary hyperparathyroidism (SHPT): Develops from the combination of hyperphosphatemia, hypocalcemia, and vitamin D deficiency, with additional contributions from reduced vitamin D receptors and calcium sensors in parathyroid tissue 3
Bone-Level Effects
Hyperphosphatemia decreases osteocyte viability and increases bone resistance to PTH, while hypophosphatemia impairs mineralization 4. Similarly, hypocalcemia promotes mineralization defects and stimulates PTH, whereas hypercalcemia suppresses PTH and reduces osteocyte viability 4.
Classification of Bone Turnover Types
ROD manifests in distinct histologic patterns based on bone turnover state 5, 3:
High Turnover Disease (Osteitis Fibrosa)
- Increased osteoclastic and osteoblastic activity
- Elevated PTH levels
- Historically more common, now declining in prevalence 2
Low Turnover Disease (Adynamic Bone Disease)
- Most common type in current CKD populations 6
- Reduced bone formation and resorption
- Low PTH levels
- Associated with oversuppression of PTH or aluminum toxicity (now rare) 5
Mixed Disease and Osteomalacia
- Combined features of high and low turnover
- Mineralization defects
- Previously often aluminum-related 5
Clinical Features and Consequences
ROD significantly increases fracture risk: 2-fold to 100-fold higher in adults and 2-fold to 3-fold higher in children with CKD compared to those without 7. Additional clinical manifestations include 2, 7:
- Bone pain and skeletal deformities
- Reduced quality of life
- Increased cardiovascular morbidity and mortality (linked to elevated PTH and calcium-phosphate product)
- Growth retardation in children
Laboratory Abnormalities
Serial assessment of biochemical markers is essential, as therapeutic interventions affecting one parameter often have unintended effects on others 8:
Key Biochemical Parameters
- PTH: Progressively rising or persistently elevated above upper normal limit warrants evaluation 8. Modest increases may represent appropriate adaptation to declining kidney function 8
- Phosphate: Hyperphosphatemia in overt cases requires treatment; aggressive lowering in non-dialysis patients lacks outcome benefit and raises safety concerns 8
- Calcium: Hypercalcemia is harmful across all CKD stages; avoid inappropriate calcium loading 8
- 25-(OH)D: Vitamin D deficiency should be corrected, though supplementation beyond biochemical correction lacks proven clinical benefit in general CKD populations 4. In kidney transplant recipients, maintaining levels ≥30 ng/ml may optimize bone health 4
Bone Turnover Markers
Bone-specific alkaline phosphatase (bALP) and intact PTH can assist in assessing bone turnover status 6, though they cannot definitively distinguish ROD subtypes.
Diagnostic Evaluation
Bone Mineral Density Testing
DXA BMD testing should be performed if results will influence treatment decisions 8. However, DXA cannot distinguish among ROD types and may underestimate fracture risk in CKD 8.
Bone Biopsy
Bone biopsy remains the gold standard for diagnosing ROD, detecting defects in turnover and mineralization that cannot be determined noninvasively 4, 8. The unified classification system reports parameters of turnover, mineralization, and volume 1.
In patients with CKD G3a to G5D with biochemical abnormalities and low BMD or fragility fractures, consider bone biopsy when treatment choices depend on accurate diagnosis of underlying bone phenotype 8. However, most treatment decisions are made without biopsy in clinical practice 4.
Management Approach
Treatment must be personalized based on fracture risk profile, bone turnover type, severity of biochemical abnormalities, cardiovascular risk, and CKD progression 4. Co-management between nephrology and bone specialists is indicated 4.
Foundational Interventions
Maintain calcium and phosphate at adequate levels for bone health 4:
- Phosphate management: Restrict dietary phosphate intake for overt hyperphosphatemia, considering phosphate source (animal vs. vegetable vs. additives) 8. Use phosphate binders judiciously; restrict calcium-based binders due to harm from excess calcium exposure 8
- Calcium management: Avoid hypercalcemia and inappropriate calcium loading across all CKD stages 8
- Vitamin D: Correct deficiency, though routine supplementation lacks proven benefit beyond biochemical correction 4
PTH Management
For CKD G3a-G5 not on dialysis: Treat progressively rising or persistently elevated PTH after addressing modifiable factors (hyperphosphatemia, hypocalcemia, high phosphate intake, vitamin D deficiency) 8. Do not routinely use calcitriol or vitamin D analogues due to hypercalcemia risk; reserve for severe, progressive hyperparathyroidism in CKD G4-G5 8.
For dialysis patients (CKD G5D): Calcimimetics, calcitriol, and vitamin D analogues are acceptable first-line options in alphabetical order, with choice guided by concomitant therapies and current calcium/phosphate levels 8.
Bone-Targeted Therapies
In patients with CKD G3a to G5D with biochemical abnormalities and low BMD or fragility fractures, treatment choices must account for the magnitude and reversibility of biochemical abnormalities and CKD progression, with consideration of bone biopsy 8.
Critical Caveats
- Antiresorptives (bisphosphonates) exacerbate low bone turnover 8
- Denosumab may induce significant hypocalcemia 8
- Do not withhold antiresorptive therapy in high fracture risk patients when bone biopsy is unavailable 8
- Knowledge of bone turnover status (via markers or biopsy) influences choice of bone-targeted therapies 4
Emerging Considerations
High-resolution peripheral quantitative CT and transcriptomic analyses show promise but require further validation for clinical use 4. Treatment strategies should be tailored to individual turnover type, with recognition that low-turnover bone disease lacks prospective outcome data demonstrating different clinical outcomes compared to non-low-turnover bone 4.